Drug intelligence / Profile preview

carboplatin + etrumadenant + pemetrexed + zimberelimab

Development stage: Unknown
Lead developer: Arcus Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **carboplatin**, an alkylating agent used in chemotherapy; **etrumadenant (AB928)**, a dual A2aR and A2bR antagonist; **pemetrexed**, an antifolate drug; and **zimberelimab (AB122)**, an anti-PD-1 antibody. The combination is being studied for its safety, tolerability, and clinical activity in non-squamous non-small cell lung cancer (NSCLC).

Brand names: Alimta
Other names: pemetrexedcarboplatin

Targets

ADORA2B (Adenosine A2B receptor)ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on carboplatin + etrumadenant + pemetrexed + zimberelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + etrumadenant + pemetrexed + zimberelimab.

Explore the full profile